FluoroPharma Medical Inc. announced the acceptance of the first comparative data from it's Phase II trial of CardioPET in subjects with a high likelihood of coronary artery disease. The abstract was accepted for oral presentation on September 24, 2016 in Boca Raton, Florida. CardioPET is a Fluorine-18 labeled modified fatty acid that mimics the heart's primary energy source, and provides insight to coronary blood flow and metabolism. Metabolic disorders are common with the high rates of CAD throughout the developed world. The trial was designed to evaluate the uptake and distribution of CardioPET in comparison to the standard of care for patients with known or suspected CAD, SPECT imaging with Tc-99m agents. Subjects were enrolled based on abnormal SPECT findings indicating ischemia.